PD-1inhibitor
Phase 3Small molecule
PD-1inhibitor is one of 60 small molecule programs targeting Esophageal Cancer. It is currently in Phase 3.
2
Indications
5
Total Trials
4
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
93 competitors in Esophageal Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Eloxatin
TevaPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Paraplatin
AAvyxa
Phase 3
Herceptin
RochePhase 3
Keytruda
Merck & Co.Phase 3
Beyfortus
BeiGenePhase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Perjeta
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Immunochemotherapy2 trials
PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT05980715·324 enrolled
PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006)
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT07090707·50 enrolled
Esophageal Cancer1 trial
Adenocarcinoma1 trial
Gastric Cancer1 trial
A Randomized Controlled Study of 2nd-line Treatment of Advanced G/GEJ Adenocarcinoma With Fruquintinib and Albumin-paclitaxel in Combination With or Without PD-1 Antibody in Patients Who Have Failed Treatment With PD-1 Antibody
Recruiting·CCancer Institute and Hospital, Chinese Academy of Medical Sciences··NCT06417892·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PD-1inhibitor. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details